Mihaela Munteanu

Gheorghe Asachi Technical University of Iași — Romania

Medicine · Health Sciences

16h-index1.7kcitations124works4.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(18), Lymphoma Diagnosis and Treatment(16), Cancer Immunotherapy and Biomarkers(14), Chronic Myeloid Leukemia Treatments(9), Lung Cancer Treatments and Mutations(8)

Publications124 total

Clinico-functional particularities of deceased patients with STEMI and NSTEMI 12 months after revascularization
Bulletin of the Academy of Sciences of Moldova Medical Sciences·2025Open Access
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study
The Lancet Respiratory Medicine·2025· 2 cited
Leakage assessment using trend detection in monthly average data series with impact on water resources provision
Journal of Physics Conference Series·2025Open Access
A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC).
Journal of Clinical Oncology·2025
Experience of patients with HIV and squamous cell carcinoma of the anal canal (SCAC) treated with retifanlimab.
Journal of Clinical Oncology·2025
Predictors of 1-year follow-up period MACE in patients with NSTEMI
European Heart Journal·2024
Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
International Journal of Gynecological Cancer·2024· 6 citedOpen Access
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
BMC Cancer·2024· 10 citedOpen Access
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
BMC Cancer·2024· 14 citedOpen Access
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
BMC Cancer·2024· 10 citedOpen Access
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
BMC Cancer·2024· 9 citedOpen Access
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study
BMC Cancer·2024· 9 citedOpen Access
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
BMC Cancer·2024· 18 citedOpen Access
Updates in the management of patients with non-obstructive coronary artery disease
Bulletin of the Academy of Sciences of Moldova Medical Sciences·2024Open Access
MACE prediction in patients with STEMI and NSTEMI: from classic to novel markers in the estimation of coronary microcirculation disorder
Bulletin of the Academy of Sciences of Moldova Medical Sciences·2024Open Access
Prediction factors of in-hospital mortality in NSTEMI
Bulletin of the Academy of Sciences of Moldova Medical Sciences·2024Open Access
Clinical features in patients with non-ST-segment elevation myocardial infarction with nonobstructive coronary arteries
Bulletin of the Academy of Sciences of Moldova Medical Sciences·2024Open Access
Functional traits of the heart in post-infarction myocardial remodeling
Bulletin of the Academy of Sciences of Moldova Medical Sciences·2024Open Access
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer
Investigational New Drugs·2024· 4 citedOpen Access
Circulating NETosis markers in NSTEMI and predicting of 1-year cardiac death
European Heart Journal·2023Open Access
page 1 of 7Next →

Frequent Co-authors

Ian W. Flinn(7), Brad S. Kahl(7), John M. Burke(7), Peter Wood(6), Tim E. Hawkins(6), David MacDonald(6), Mark Hertzberg(6), David Simpson(6), Michael Craig(6), Kathryn S. Kolibaba(6), Samar Issa(6), Yiu‐Lam Kwan(5), Regina Clementi(5), Lance Leopold(5), Ayman Samkari(5), Myron S. Czuczman(4), Doreen M. Hallman(3), Cristina Gavrilovici(3), H. Jean Khoury(3), Richard H. van der Jagt(3)